Natera, Inc. · NASDAQ:NTRA
Natera — 44th Annual J.P. Morgan Healthcare Conference 2026
16 slides from Natera's conference presentation, Jan 13, 2026
Slide 1: Natera, Inc. Investor presentation
Natera, Inc. Investor presentation J.P. Morgan Healthcare Conference January 13, 2026 1
Slide 2: Safe harbor statement
Safe harbor statement This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our market opportunity, our a
Slide 3: Our mission: Transforming the management of disease worldwide
OUR MISSION Transforming the management of disease worldwide 3 Not for reproduction or further distribution.
Slide 4: A leader in cell-free DNA technology addressing large, underpenetrated markets
A leader in cell-free DNA technology addressing large, underpenetrated markets tests >16M processed 2013 2019 PanoramaTM NIPT launch peer-reviewed >350 publications ONCOLOGY issued or >600 pending patents WOMEN’S HEALTH ORGAN HEALTH >6K employees NOTE: Numbers cited as of 12/31/25. 4 Not for reprodu
Slide 5: Formula for success
Formula for success Leading-edge technology and constant innovation Leader in peer-reviewed, published clinical data Excellent customer/patient experience Broad and talented commercial teams 5 Not for reproduction or further distribution.
Slide 6: Record volumes in Q4
Record volumes in Q4 1000K 924K Core Volume Drivers 900K 793K • Continued momentum 800K across products 700K 627K • Record sequential 600K 560K growth for SignateraTM 500K 439K • Strong growth and 400K significant interest in 295K 300K Fetal FocusTM 200K • Organ health data driving volume ramp 100K
Slide 7: Clinical MRD volumes: another record quarter
Clinical MRD1 volumes: another record quarter 250K Clinical MRD tests processed ~22.8K 225K • Fastest unit growth 230K quarter at ~22.8K volume 210K 202K growth 190K 181K • Acceleration seen across multiple tumor types 170K 161K 145K • Strong data readouts 150K driving volume 130K 130K acceleration
Slide 8: Revenues up ~39% over Q4 2024
Revenues up ~39% over Q4 2024 $700M Total revenues: YoY Q4 trend $660M • Strong ASP trends across women’s health, organ ~39% $600M health, and oncology • Continue to gain share in $500M $476M women’s health and organ health $400M • Signatera continues to $311M ramp $300M • Greater than $100M in $217
Slide 9: Announcing launch of 21-gene Fetal Focus single-gene NIPT
Announcing launch of 21-gene Fetal Focus single-gene NIPT EXPAND Readout1,2 Ultrasensitive technology: utilizes Natera’s proprietary LinkedSNP technology. 96% sensitivity Broad assessment: fetal risk assessment for 21 recessive and X- linked genes. 98% specificity Flexible ordering: available as a f
Slide 10: Complete product portfolio for MRD detection
Complete product portfolio for MRD detection Tumor-informed Signatera Signatera Tissue-free designed on Exome designed on Genome MRD (CRC) • Most extensively • Leverages proven • Launched in mid-2025 validated, adopted, mPCR-NGS approach • Other tumor types and reimbursed MRD to follow • LOD down to
Slide 11: Acquisition of Foresight Diagnostics
Acquisition of Foresight Diagnostics Ultrasensitive phased variant technology • Performance with LOD95 of 3 parts per 10 million and detection below 1 Single nucleotide variant (SNV) part per 10 million. • Signatera platform with phased variants now available for research use. Strong clinical positi
Slide 12: Natera AI unlocking next major innovation in MRD and precision oncology
Natera AI unlocking next major innovation in MRD and precision oncology Digital pathology Tumor and normal Signatera MRD Longitudinal clinical and images Exome/Genome +/- RNA Longitudinal dynamics treatment data with AI-enabled (>300K patients) (>1M timepoints) data abstraction at scale + + + Natera
Slide 13: Key readouts and trial announcements
Key readouts and trial announcements Key Readouts Recent Trial in 2025 Announcements IMvigor011 MiRaDoR Checkmate 274 HEROES PALLAS TEODOR I-SPY 2 ARCHER DARE STELLAR-316 CALGB (Alliance)/SWOG 80702 INTERCEPT PROCEED-CRC 13 Not for reproduction or further distribution.
Slide 14: TOMR trial in colorectal cancer with Exelixis
TOMR trial in colorectal cancer with Exelixis STELLAR-316: Key Details STELLAR-316: Interventional Study Design • Phase III pivotal trial, initiating in mid- 2026 • Resected stage II/III colorectal cancer Zanzalintinib + ICI • TOMR approach: patients will be Commercial Signatera- Completion randomiz
Slide 15: FIND-CRC: initiated in 2025, continuing to make significant progress
FIND-CRC1: initiated in 2025, continuing to make significant progress FIND CRC: FDA-enabling study Targeting 25k-40k average-risk adults; 70 CRC cases, ~1,400 AA cases First patient in: May 2025 Enrollment expected to be completed in 2026 1. NCT: NCT07046585. 15 Not for reproduction or further distr
Slide 16: Anticipated 2026 Milestones
Anticipated 2026 Milestones Expanded MolDX coverage Integration of Foresight Diagnostics Signatera with phased and structural variants Signatera in Japan Latitude for additional cancer types Fetal Focus launch Enrollment completion for the FIND study Collaborations in AI (NVIDIA) and sequencing (Ult
Natera — 44th Annual J.P. Morgan Healthcare Conference 2026 on 6ix